What's Going On With Longevity Health Shares Monday?
Longevity Health Holdings, Inc. (NASDAQ:XAGE shares are soaring on Monday after the company announced it entered into a merger agreement with 20/20 BioLabs, Inc., a provider of testing for the early detection and management of chronic disease.
The Details: The deal, which follows Longevity's January acquisition of Elevai Skincare, aligns with the company's strategy to expand into diagnostics to build synergies with its existing bio-aesthetics portfolio, as well as its contemplated expansion into nutrition.
20/20 BioLabs offers OneTest, a multi-cancer early detection blood test, and is preparing to launch a new “longevity test” that analyzes biomarkers tied to aging and chronic disease. The combined company anticipates over $1 million in operational savings and potential cross-selling across both customer bases.
The merger is expected to double Longevity’s fiscal-year 2025 anticipated revenue from approximately $3-4 million to approximately $7-8 million.
The merger is expected to close in the third quarter of 2025, subject to shareholder approval and other customary closing conditions.
See Also: Crude Oil Moves Lower; M&T Bank Earnings Miss Views
XAGE Price Action: At the time of publication, Longevity shares are trading 51.7% higher at 19 cents, according to data from Benzinga Pro.
Image: via Shutterstock
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
English